Related Experiment Video
Updated: May 3, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.5K
Risk estimation in rheumatoid arthritis: from bench to bedside
Annette H M van der Helm-van Mil1
1Department of Rheumatology, Leiden University Medical Centre, P. O. Box 9600, 2300 RC Leiden, Netherlands.
Nature Reviews. Rheumatology
|January 29, 2014
Summary
Rheumatoid arthritis (RA) outcomes have improved due to earlier treatment and new drugs. However, personalized treatment decisions are still limited by the lack of accurate prognostic tools for individual patients.
Area of Science:
- Rheumatology
- Clinical Epidemiology
Background:
- Prognosis for rheumatoid arthritis (RA) patients diagnosed since 2010 has significantly improved compared to those diagnosed two decades ago.
- This improvement stems from earlier treatment initiation, disease-activity-guided therapy adjustments, and novel effective medications.
Purpose of the Study:
- To discuss methods for evaluating predictive model performance in RA.
- To highlight advances in risk estimation for key clinical decisions in RA management.
- To address the limitations in current prognostic tools for personalized RA treatment.
Main Methods:
- Review of methods for evaluating predictive model performance.
- Discussion of risk estimation advances for specific RA treatment decisions.
- Analysis of the accuracy and validation status of existing prognostic tools.
Main Results:
- Current RA treatment strategies are largely population-based, not individualized.
- Prognostic tools for RA are often inaccurate or lack validation, hindering personalized care.
- Advances in risk estimation exist for specific decisions like DMARD initiation and treatment intensity.
Conclusions:
- Despite improved RA outcomes, personalized treatment remains a challenge.
- Validated and accurate prognostic models are crucial for advancing individualized RA care.
- Bridging the gap between research and clinical practice for personalized RA treatment is essential.
More Related Videos
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:20The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K
01:23Rheumatic Heart Disease I: Introduction
1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
01:21Rheumatic Heart Disease III: Medical Management
544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544